SHTG Digest — Friday May 22, 2026

A landmark ACC/AHA dyslipidemia guideline dropped this week alongside a pivotal Circulation imaging trial showing olezarsen's dramatic triglyceride reduction does not translate into coronary plaque regression — a sobering finding that reframes what APOC3 inhibition can and cannot achieve at 12 months; on the industry side, the two biggest near-term catalysts remain Ionis' June 30 PDUFA date for olezarsen in sHTG and Arrowhead's expected EU approval of REDEMPLO, both just outside this cycle's lookback window but essential context.